SCHEMBL26824285

SCHEMBL26824285

CC(C)C[C@H]1OC(OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)[C@H](C)[C@H]1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGALS9 O00182 1/20 0.42
▸ LGALS1 P09382 1/20 0.42
▸ LGALS3 P17931 1/20 0.42
▸ LGALS7; LGALS7B P47929 1/20 0.42
▸ PTPN1 P18031 3/20 0.39
▸ NT5E P21589 1/20 0.39
▸ BCHE P06276 1/20 0.38
▸ SELP P16109 8/20 0.38
▸ SELE P16581 2/20 0.38
▸ TRPM8 Q7Z2W7 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ ADRB2 P07550 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ ADRB3 P13945 1/20 0.36
▸ HTR3E A5X5Y0 1/20 0.36
▸ HTR3B O95264 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ HTR3A P46098 1/20 0.36
▸ HTR3D Q70Z44 1/20 0.36
▸ HTR3C Q8WXA8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26824308 1.00 LGALS9 (0.42) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL16489268 0.86 LGALS9 (0.44) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL17773533 0.86 LGALS9 (0.44) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL17773524 0.86 LGALS3 (0.53) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL18067737 0.84 PTPN1 (0.53) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL11981201 0.84 PTPN1 (0.53) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL26824136 0.84 LGALS9 (0.43) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL12292268 0.84 PTPN1 (0.53) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL16904875 0.82 LGALS9 (0.45) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1
SCHEMBL12150947 0.82 LGALS9 (0.45) LGALS9LGALS1LGALS3LGALS7; LGALS7BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway REATA PHARMACEUTICALS, INC (US) 2023-11-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827664-B2 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway HSPA2, HSP90AB2P, HSF1 LGALS9 3109/4885LGALS1 2570/4885LGALS3 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback